TABLE 3

Tumor Dosimetry for Principal Radiopharmaceuticals Used in PRRT

Radiopharmaceutical	Tumor mass (g)	Absorbed dose (mGy/MBq)	Reference
¹¹¹In-DTPA-octreotide	1 g^*	6.9	(30)
	10 g^*	0.7	(30)
		2.8, for RBE = 1	(18)
		11.2, for RBE = 20	(18)
	100 g^*	0.4, for RBE = 1	(18)
		1.3, for RBE = 20	(18)
⁹⁰Y-DOTATOC	9 lesions (mass not specified)	Range = 2.4–41.7^†	(16)
	23 lesions; range = 2–115 g	Range = 1.4–31.0^†	(15)
	Mass not specified	Range = 2.1–29.5^‡	(23)
¹⁷⁷Lu-DOTATATE	1 g^*	37.9	(30)
	10 g^*	3.9	(30)

↵* Tumor masses considered for theoretic tumor dose evaluations.
↵† ¹¹¹In-DOTATOC used as radiotracer.
↵‡ ⁸⁶Y-DOTATOC used as radiotracer.
RBE = relative biologic effectiveness; ¹¹¹In-DTPA-octreotide = [¹¹¹In-DTPA⁰,d-Phe¹]octreotide; ⁹⁰Y-DOTATOC = [⁹⁰Y-DOTA,Tyr³]octreotide; ¹⁷⁷Lu-DOTATATE = [¹⁷⁷Lu-DOTA⁰,Tyr³,Thr⁸]octreotide.